193 related articles for article (PubMed ID: 27012201)
1. TRIM65 negatively regulates p53 through ubiquitination.
Li Y; Ma C; Zhou T; Liu Y; Sun L; Yu Z
Biochem Biophys Res Commun; 2016 Apr; 473(1):278-282. PubMed ID: 27012201
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
Pan X; Chen Y; Shen Y; Tantai J
Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
[TBL] [Abstract][Full Text] [Related]
3. Combinatory inhibition of TRIM65 and MDM2 in lung cancer cells.
Chen G; Zhou T; Liu Y; Yu Z
Biochem Biophys Res Commun; 2018 Nov; 506(3):698-702. PubMed ID: 30454706
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of TRIM65 inhibits lung cancer cell proliferation, migration and invasion: A therapeutic target in human lung cancer.
Wang XL; Shi WP; Shi HC; Lu SC; Wang K; Sun C; He JS; Jin WG; Lv XX; Zou H; Shu YS
Oncotarget; 2016 Dec; 7(49):81527-81540. PubMed ID: 27829229
[TBL] [Abstract][Full Text] [Related]
5. TRIM65 triggers β-catenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Zhang CZ
J Cell Sci; 2017 Sep; 130(18):3108-3115. PubMed ID: 28754688
[TBL] [Abstract][Full Text] [Related]
6. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.
Zhong T; Zhang J; Liu X; Li H
Cell Oncol (Dordr); 2023 Oct; 46(5):1493-1507. PubMed ID: 37219768
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-protein ligase E3C maintains non-small-cell lung cancer stemness by targeting AHNAK-p53 complex.
Gu J; Mao W; Ren W; Xu F; Zhu Q; Lu C; Lin Z; Zhang Z; Chu Y; Liu R; Ge D
Cancer Lett; 2019 Feb; 443():125-134. PubMed ID: 30503554
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
9. TRIM65 supports bladder urothelial carcinoma cell aggressiveness by promoting ANXA2 ubiquitination and degradation.
Wei WS; Chen X; Guo LY; Li XD; Deng MH; Yuan GJ; He LY; Li YH; Zhang ZL; Jiang LJ; Chen RX; Ma XD; Wei S; Ma NF; Liu ZW; Luo JH; Zhou FJ; Xie D
Cancer Lett; 2018 Oct; 435():10-22. PubMed ID: 30075204
[TBL] [Abstract][Full Text] [Related]
10. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
Hu C; Zhang M; Moses N; Hu CL; Polin L; Chen W; Jang H; Heyza J; Malysa A; Caruso JA; Xiang S; Patrick S; Stemmer P; Lou Z; Bai W; Wang C; Bepler G; Zhang XM
Cell Death Dis; 2020 May; 11(5):328. PubMed ID: 32382008
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
12. TRIM65 E3 ligase targets VCAM-1 degradation to limit LPS-induced lung inflammation.
Li Y; Huang X; Guo F; Lei T; Li S; Monaghan-Nichols P; Jiang Z; Xin HB; Fu M
J Mol Cell Biol; 2020 Apr; 12(3):190-201. PubMed ID: 31310649
[TBL] [Abstract][Full Text] [Related]
13. Silencing of the SNARE protein NAPA sensitizes cancer cells to cisplatin by inducing ERK1/2 signaling, synoviolin ubiquitination and p53 accumulation.
Wu ZZ; Sun NK; Chien KY; Chao CC
Biochem Pharmacol; 2011 Dec; 82(11):1630-40. PubMed ID: 21903092
[TBL] [Abstract][Full Text] [Related]
14. TRIM65 promotes renal cell carcinoma through ubiquitination and degradation of BTG3.
Zhang Q; Li Y; Zhu Q; Xie T; Xiao Y; Zhang F; Li N; Deng K; Xin H; Huang X
Cell Death Dis; 2024 May; 15(5):355. PubMed ID: 38777825
[TBL] [Abstract][Full Text] [Related]
15. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Yan W; Jung YS; Zhang Y; Chen X
PLoS One; 2014; 9(8):e103497. PubMed ID: 25116336
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation.
Chen D; Li Y; Zhang X; Wu H; Wang Q; Cai J; Cui Y; Liu H; Lan P; Wang J; Yang Z; Wang L
Oncogene; 2019 Sep; 38(37):6429-6444. PubMed ID: 31332286
[TBL] [Abstract][Full Text] [Related]
18. RNF125 is a ubiquitin-protein ligase that promotes p53 degradation.
Yang L; Zhou B; Li X; Lu Z; Li W; Huo X; Miao Z
Cell Physiol Biochem; 2015; 35(1):237-45. PubMed ID: 25591766
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of TRIM65 suppressed the proliferation and invasiveness of gastric cancer cells by restricting the ubiquitin degradation of PPM1A.
Liu C; Sun W; Yang K; Xia B
Exp Cell Res; 2022 Jul; 416(2):113154. PubMed ID: 35421368
[TBL] [Abstract][Full Text] [Related]
20. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
Hu Z; Zeng Q; Zhang B; Liu H; Wang W
Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
